Therefore, these agents are only used for NSCLC patients harboring EGFR-sensitive mutations but could not benefit sufferers harboring the T790M mutant.79,80,82 Novel pyrimidine-based third-generation EGFR TKIs have inhibitory effects on EGFR-activating mutations and the T790M mutation specifically but show weak inhibitory activity on wild-type EGFR. Here, EGFR is linked to non-small cell lung carcinoma.